130 related articles for article (PubMed ID: 37309299)
1. Microfluidic Synthesis of Ultrasmall Chitosan/Graphene Quantum Dots Particles for Intranasal Delivery in Alzheimer's Disease Treatment.
Mohebichamkhorami F; Faizi M; Mahmoudifard M; Hajikarim-Hamedani A; Mohseni SS; Heidari A; Ghane Y; Khoramjouy M; Khayati M; Ghasemi R; Zali H; Hosseinzadeh S; Mostafavi E
Small; 2023 Oct; 19(40):e2207626. PubMed ID: 37309299
[TBL] [Abstract][Full Text] [Related]
2. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
3. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
4. Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's β-Amyloid.
Wang W; Liu M; Gao W; Sun Y; Dong X
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55879-55889. PubMed ID: 34786930
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
6.
Zhang L; Yang S; Wong LR; Xie H; Ho PC
Mol Pharm; 2020 Nov; 17(11):4256-4269. PubMed ID: 33084343
[TBL] [Abstract][Full Text] [Related]
7. Graphene quantum dots for the inhibition of β amyloid aggregation.
Liu Y; Xu LP; Dai W; Dong H; Wen Y; Zhang X
Nanoscale; 2015 Dec; 7(45):19060-5. PubMed ID: 26515666
[TBL] [Abstract][Full Text] [Related]
8. pH-sensitive drug delivery based on chitosan wrapped graphene quantum dots with enhanced fluorescent stability.
Sheng Y; Dai W; Gao J; Li H; Tan W; Wang J; Deng L; Kong Y
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110888. PubMed ID: 32409046
[TBL] [Abstract][Full Text] [Related]
9. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML
J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747
[TBL] [Abstract][Full Text] [Related]
10. Highly fluorescent and morphology-controllable graphene quantum dots-chitosan hybrid xerogels for in vivo imaging and pH-sensitive drug carrier.
Lv O; Tao Y; Qin Y; Chen C; Pan Y; Deng L; Liu L; Kong Y
Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():478-485. PubMed ID: 27287145
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in synergistic use of GQD-based hydrogels for bioimaging and drug delivery in cancer treatment.
Akmal MH; Kalashgrani MY; Mousavi SM; Rahmanian V; Sharma N; Gholami A; Althomali RH; Rahman MM; Chiang WH
J Mater Chem B; 2024 May; 12(21):5039-5060. PubMed ID: 38716622
[TBL] [Abstract][Full Text] [Related]
13. Brain targeted peptide-functionalized chitosan nanoparticles for resveratrol delivery: Impact on insulin resistance and gut microbiota in obesity-related Alzheimer's disease.
Yang L; Wang Y; Li Z; Wu X; Mei J; Zheng G
Carbohydr Polym; 2023 Jun; 310():120714. PubMed ID: 36925241
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease.
Gupta J; Fatima MT; Islam Z; Khan RH; Uversky VN; Salahuddin P
Int J Biol Macromol; 2019 Jun; 130():515-526. PubMed ID: 30826404
[TBL] [Abstract][Full Text] [Related]
15. Graphene quantum dots obstruct the membrane axis of Alzheimer's amyloid beta.
Tang H; Li Y; Kakinen A; Andrikopoulos N; Sun Y; Kwak E; Davis TP; Ding F; Ke PC
Phys Chem Chem Phys; 2021 Dec; 24(1):86-97. PubMed ID: 34878460
[TBL] [Abstract][Full Text] [Related]
16. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
17. Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation.
Liu Y; Xu LP; Wang Q; Yang B; Zhang X
ACS Chem Neurosci; 2018 Apr; 9(4):817-823. PubMed ID: 29244487
[TBL] [Abstract][Full Text] [Related]
18. Chrysin-Loaded Chitosan Nanoparticle-Mediated Neuroprotection in Aβ
Saleem S; Banerjee R; Rajesh Kannan R
ACS Chem Neurosci; 2022 Jul; 13(13):2017-2034. PubMed ID: 35696319
[TBL] [Abstract][Full Text] [Related]
19. Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems.
Han Y; Chu X; Cui L; Fu S; Gao C; Li Y; Sun B
Drug Deliv; 2020 Dec; 27(1):502-518. PubMed ID: 32228100
[TBL] [Abstract][Full Text] [Related]
20. Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer's Disease.
Manek E; Darvas F; Petroianu GA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33096898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
